Amiral Gestion Has $19.33 Million Stake in Edwards Lifesciences Corporation $EW

Amiral Gestion trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 19.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 226,710 shares of the medical research company’s stock after selling 56,085 shares during the quarter. Edwards Lifesciences makes up approximately 7.0% of Amiral Gestion’s portfolio, making the stock its 5th biggest holding. Amiral Gestion’s holdings in Edwards Lifesciences were worth $19,327,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $25,000. True Wealth Design LLC grew its position in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. Rakuten Securities Inc. grew its holdings in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Hantz Financial Services Inc. increased its stake in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. purchased a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EW. UBS Group restated a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Wells Fargo & Company boosted their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Citigroup reiterated a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $96.14.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $85.93, for a total value of $974,446.20. Following the completion of the transaction, the vice president owned 21,266 shares of the company’s stock, valued at $1,827,387.38. This represents a 34.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the sale, the vice president directly owned 33,934 shares in the company, valued at $2,897,284.92. This trade represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,718 shares of company stock worth $5,236,281 in the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 3.1%

NYSE EW opened at $79.54 on Friday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $46.20 billion, a P/E ratio of 43.47, a price-to-earnings-growth ratio of 2.14 and a beta of 0.93. The stock’s 50-day moving average price is $82.02 and its 200-day moving average price is $81.66.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the prior year, the company posted $0.59 earnings per share. The company’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.